Generating clinically compliant iPSC lines is one of the biggest bottlenecks in allogeneic cell therapy — research-grade lines that later need re-derivation under GMP cause rework, delays, and added cost.
In a poster presented at the ISSCR’s Annual Meeting in Montréal, Canada, Suzanne Snellenberg shows how Cellistic’s Pulse™ platform builds ATMP-compliant Allo Chassis™ iPSC lines from the outset: donor-derived starting material, non-integrative reprogramming, and STAR-CRISPR™ gene editing to knock out B2M and CIITA, yielding HLA class I/II–null, immune-evasive lines with fully validated clonality and off-target safety.
The result is a GMP-aligned starting point that removes a major rework cycle between R&D and CDMO handoff.